Added to YB: 2026-07-27
Pitch date: 2026-07-24
MEDP [neutral]
Medpace Holdings, Inc.
Author Info
Expanse Stocks is a research-driven newsletter on equities & long-term investing. Sign up for the newsletter.
Company Info
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Market Cap
$16.9B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
25.24
P/E
35.52
EV/Sales
5.95
Sector
Life Sciences Tools and Services
Category
growth
Medpace Q2 2026
MEDP (earnings): Q2'26 rev +17.2% YoY to $707.3M, EBITDA +17.6% to $153.4M; raised FY guidance across board. Net book-to-bill recovered to 1.13x (bookings +28.2%), refuting Q1 0.88x bear thesis. Oncology now >50% of bookings, killing GLP-1 'metabolic cliff' fear. RFPs up meaningfully; $294.7M opportunistic buybacks. Watch: 24.1% conversion rate reverting to ~18% norm; pass-through mix pressuring margins. EPS guide $17.25-17.95 (+17.5%) excl. buybacks.
Read full article (6 min)